For patients using currently available injectable GLP-1 medications , common errors include injecting into the same site repeatedly, failing to allow refrigerated medication to reach room temperature before injection, not rotating injection sites properly, and incorrect pen device technique
B.et al (2001)
A study conducted by the InfantRisk Center found that tirzepatide was either undetectable or present in extremely small amounts in breast milk at doses up to 5 mg , and no adverse effects were observed in the infants involved in the study
Advertisement From the results of the trials weve seen, the recommendation is to continue taking GLP-1s for as long as possible and to think of obesity as a chronic disease, explains Dr
Individual results vary depending on factors such as lifestyle, diet, and unique body chemistry
The automated self-administered 24-hour dietary recall (ASA24): a resource for researchers, Clinicians, and educators from the national cancer institute
